PharmaCyte Biotech (PMCB) Total Debt (2011 - 2021)

PharmaCyte Biotech (PMCB) posted quarterly Total Debt of $141953.0 for Q1 2021, up 9.78% quarter-over-quarter from $129310.0 in Q4 2020.

PharmaCyte Biotech (PMCB) Total Debt (2011 - 2021) Analysis & Trends

PharmaCyte Biotech (PMCB) has reported Total Debt for 6 consecutive years, with $141953.0 the latest figure, recorded in Q1 2021.

In Q1 2021, Total Debt changed N/A year-over-year to $141953.0; the TTM figure through Jan 2021 stood at $141953.0 (changed N/A YoY), while the FY2020 annual figure was $75200.0, changed N/A from the prior year.
Total Debt improved to $141953.0 in Q1 2021 per PMCB's latest filing, from $129310.0 in the prior quarter.
Across five years, Total Debt topped out at $141953.0 in Q1 2021 and bottomed at $75200.0 in Q2 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Total Debt (Qtr)
1	Vertex Pharmaceuticals	139.24 Bn	131.39 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	86.01 Bn	78.02 Bn	3.93 Bn	1.99 Bn
3	Argenx Se	65.61 Bn	60.42 Bn	1.37 Bn	-
4	Moderna	56.92 Bn	51.78 Bn	52.00 Mn	591.00 Mn
5	BeOne Medicines	42.17 Bn	37.07 Bn	1.53 Bn	1.07 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.27 Bn	992.69 Mn	-
7	BioNTech SE	27.77 Bn	9.38 Bn	668.28 Mn	770.36 Mn
8	Insmed	27.52 Bn	26.36 Bn	358.27 Mn	546.77 Mn
9	Royalty Pharma	27.36 Bn	26.52 Bn	-	9.34 Bn
10	PharmaCyte Biotech	4.48 Mn	4.48 Mn	-	-

Download Data